Is UZEDY Approved for Bipolar Disorder?
No, UZEDY (risperidone extended-release injectable suspension) is FDA-approved only for schizophrenia in adults.[1] It is not approved for bipolar disorder or bipolar mania.
How Does UZEDY Work and What Is It Used For?
UZEDY delivers risperidone, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2 receptors to manage psychotic symptoms.[1] Teva Pharmaceuticals launched it in 2023 as a once-monthly or once-every-two-months subcutaneous injection for schizophrenia maintenance treatment, offering an alternative to daily pills.[2]
Why Not for Bipolar—Off-Label Use Possible?
Risperidone itself has FDA approval as oral tablets for bipolar I mania (with or without psychosis) in adults and children.[3] Some psychiatrists prescribe UZEDY off-label for bipolar based on this, especially for non-adherent patients needing long-acting formulations. No clinical trials support UZEDY specifically for bipolar, and Teva does not promote it for that indication.[1]
How Does UZEDY Compare to Bipolar Treatments?
| Treatment | Indication | Formulation | Dosing |
|-----------|------------|-------------|--------|
| UZEDY (risperidone) | Schizophrenia only | Monthly/2-monthly injection | 50-250 mg |
| Oral risperidone (Risperdal) | Schizophrenia, bipolar mania | Daily tablet | 1-6 mg |
| Invega Sustenna (paliperidone) | Schizophrenia, schizoaffective | Monthly injection | 39-234 mg |
| Abilify Maintena (aripiprazole) | Schizophrenia, bipolar I | Monthly injection | 300-400 mg |
Long-acting injectables like Invega or Abilify Maintena have bipolar approvals; UZEDY does not.[4]
Common Side Effects and Bipolar Patient Concerns
Patients report weight gain, drowsiness, injection-site reactions, and elevated prolactin levels with UZEDY.[1] For bipolar, off-label users worry about metabolic risks (diabetes, high cholesterol) and movement disorders like tardive dyskinesia, which occur in 5-10% of long-term antipsychotic users.[3] Extrapyramidal symptoms affect 10-20% initially.[1]
Patent Status and Availability
Teva holds U.S. patents on UZEDY's formulation through 2035-2040, with no generic competition expected soon.[5] List price is $3,000-$4,000 per monthly dose; patient assistance programs cover copays for eligible schizophrenia patients.[2]
[1]: UZEDY Prescribing Information (Teva, 2023)
[2]: FDA Approval Summary (2023)
[3]: Risperdal Prescribing Information (Janssen)
[4]: Long-Acting Injectables Comparison (Psychiatrist.com, 2024)
[5]: DrugPatentWatch.com - UZEDY Patents